Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Portola Pharmaceuticals Follow-On Offering
Davis Polk advised the joint book-running managers and the co-managers in connection with the $349.3 million…
Zoetis Inc. $1.25 Billion Senior Notes Offering
Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Zoetis Inc…
Jazz Pharmaceuticals $500 Million Exchangeable Senior Notes Offering
Davis Polk advised the initial purchasers on a Rule 144A offering by Jazz Investments I Limited, a wholly owned…
Oxford Immunotec Global PLC Offering of Ordinary Shares
Davis Polk advised the underwriter in connection with the $39.3 million SEC-registered offering of 2,500,000 ordinary…
BeiGene, Ltd. Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters on the $201 million public…
Celgene $500 Million Notes Offering
Davis Polk advised the sole book-running manager on an SEC-registered offering by Celgene Corporation of $500 million…
Spark Therapeutics Follow-On Offering
Davis Polk advised the representative of the underwriters in connection with the $402.5 million public offering of 5…
Davis Polk Advises Accuray Incorporated on Its Private Exchange Offer
Davis Polk advised Accuray Incorporated in connection with a private exchange of approximately $47 million aggregate…
$3.1 Billion Financing for inVentiv’s Merger with INC Research
Davis Polk advised the administrative agent in connection with a $3.1 billion best-efforts financing comprised of a $1…
Davis Polk Advises PharMerica on Its Acquisition by KKR and Walgreens
Davis Polk is advising PharMerica Corporation on its approximately $1.4 billion acquisition by a newly formed company…